Yung‐Yeh Su

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

Antonio D’Alessio, Bernardo Stefanini, Julia Blanter et al. · The Lancet Oncology · 2024 · 65 citations · Full text

Medicine, Oncology, Pathology +17

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort

Yung‐Yeh Su, Nai‐Jung Chiang, Hui‐Jen Tsai et al. · Scientific Reports · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

Ying‐Chun Shen, Tsung‐Hao Liu, Alan Nicholas et al. · Journal of Clinical Oncology · 2024 · 29 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives

Yung‐Yeh Su, Chia-Chen Li, Yih-Jyh Lin et al. · Seminars in Liver Disease · 2021 · 25 citations

Pharmacy, Immunology, Oncology +17

A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study

Yung‐Yeh Su, Yen‐Feng Chiu, Chung‐Pin Li et al. · British Journal of Cancer · 2021 · 24 citations · Full text

Medicine, Oncology, Chemotherapy +11